Literature DB >> 24335716

Taxanes as radiosensitizers.

Encouse B Golden1, Silvia C Formenti, Peter B Schiff.   

Abstract

In parallel with the discovery of the taxanes, our understanding of the molecular underpinnings that comprise the classic biologic principles of fractionated radiotherapy has rapidly evolved over the past half century. Early studies have implicated DNA as the primary target for radiation-induced lethality. More recently, however, the molecular biology involved in radiosensitization of tumor cells has been unveiled. Specifically, factors associated with DNA damage and cell killing, collectively known as the 'four Rs' of radiobiology, including (r)eassortment of tumor cells into the radiosensitive phases of the cell cycle (G2/M), (r)eoxygenation of hypoxic areas within a tumor, (r)epair of sublethal DNA damage, and (r)epopulation of surviving tumor cells, have been elucidated, and upon manipulation of each factor or a combination of factors a significant impact on radiation-associated tumor control probabilities was found. Not only does spatial cooperation have a theoretical benefit in patients with undetectable micrometastatic disease at presentation, but the manipulation of either of the 'four Rs' using taxanes provokes further local radiation-associated tumor cell killing with an associated improvement in clinical responses. Numerous studies have shown that taxanes radiosensitize tumor cells directly and/or indirectly by perturbing the tumor microenvironment in a time-dependent and dose-dependent manner. Herein, the impact of taxanes on radiobiological tenets as a mode of radiosensitizing tumor cells and their clinical implications are reviewed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24335716     DOI: 10.1097/CAD.0000000000000055

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  5 in total

1.  KPU-300, a Novel Benzophenone-Diketopiperazine-Type Anti-Microtubule Agent with a 2-Pyridyl Structure, Is a Potent Radiosensitizer That Synchronizes the Cell Cycle in Early M Phase.

Authors:  Kohei Okuyama; Atsushi Kaida; Yoshiki Hayashi; Yoshio Hayashi; Kiyoshi Harada; Masahiko Miura
Journal:  PLoS One       Date:  2015-12-30       Impact factor: 3.240

2.  Haloperidol Induced Cell Cycle Arrest and Apoptosis in Glioblastoma Cells.

Authors:  Fotios Papadopoulos; Rafaela Isihou; George A Alexiou; Thomas Tsalios; Evrysthenis Vartholomatos; Georgios S Markopoulos; Chrissa Sioka; Pericles Tsekeris; Athanasios P Kyritsis; Vasiliki Galani
Journal:  Biomedicines       Date:  2020-12-11

3.  Clinical Outcome in Definitive Concurrent Chemoradiation With Weekly Paclitaxel and Carboplatin for Locally Advanced Esophageal and Junctional Cancer.

Authors:  Vanita Noronha; Kumar Prabhash; Amit Joshi; Vijay Maruti Patil; Sanjay Talole; Dipti Nakti; Arvind Sahu; Srushti Shah; Sarbani Ghosh-Laskar; Prachi S Patil; Shaesta A Mehta; Nirmala Jambhekar; Abhishek Mahajan; Nilendu Purandare
Journal:  Oncol Res       Date:  2016       Impact factor: 5.574

4.  First-line cisplatin, docetaxel, and cetuximab for patients with recurrent or metastatic head and neck cancer: A multicenter cohort study.

Authors:  Agustín Falco; Mariano Leiva; Albano Blanco; Guido Cefarelli; Andrés Rodriguez; Juan Melo; Federico Cayol; Manglio Miguel Rizzo; Alejandro Sola; Hernán Rodríguez Montani; Matías Chacon; Diego Enrico; Federico Waisberg
Journal:  World J Clin Oncol       Date:  2022-02-24

5.  Combination Strategies to Improve Targeted Radionuclide Therapy.

Authors:  Tiffany G Chan; Edward O'Neill; Christine Habjan; Bart Cornelissen
Journal:  J Nucl Med       Date:  2020-10-09       Impact factor: 10.057

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.